Latest Breaking News On - Gideonm hirschfield - Page 1 : comparemela.com

Study explores potential target to treat liver disease

Study explores potential target to treat liver disease
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

David adamsGideon hirschfieldGideonm hirschfieldBirmingham biomedical research center inflammatory liver diseaseUniversity of birminghamPhepatology communicationsToronto centerAutoimmune liver disease researchUniversity of birmingham institute immunologyProfessor david adamsChris westonAssociate professorBiomedical research centerInflammatory liver diseaseClinical investigatorProfessor gideon hirschfield

Seladelpar normalizes ALP, reduces pruritis vs placebo in primary biliary cholangitis

Seladelpar normalizes ALP, reduces pruritis vs placebo in primary biliary cholangitis
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

Gideonm hirschfieldTerry hornerHeather bieleBykate burbaUniversity of torontoTerry horner chairAutoimmune liver diseaseNew england journal

Study shows seladelpar beneficial for patients with primary biliary cholangitis

Study shows seladelpar beneficial for patients with primary biliary cholangitis
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Gideonm hirschfieldBernd schnablDavidn assisUniversity health networkNew england journalPrimary biliary cholangitisAdvancing second line treatment

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

Interim results from INTEGRIS-PSC to be featured in an oral presentation on Monday, November 13SOUTH SAN FRANCISCO, Calif., Oct. 19, 2023 Pliant Therapeutics, Inc. , a clinical-stage.

United statesJohanna schaubChristopher keenanMichael traunerRichard pencekTerry hornerGideonm hirschfieldChrisn barnesHardeane achneckChristoph schrammGideon hirschfieldTheresa thuenerKrisv kowdleyAnnie clarkChristopherl bowlusPliant therapeutics inc

CymaBay Therapeutics to Present New Data Highlighting Seladelpar s Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress™ 2023

/PRNewswire/ CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other.

United statesTheresa dolgeKris kowdleyCharles mcwherterChristopherl bowlusMarlynj mayoJohnm vierlingDouglasw selingerGideonm hirschfieldCharlesa mcwherterGideon hirschfieldHans vitzthumMarye standenDavide jonesYun jung choiAndrease kremer